IMPL Impel Neuropharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMPL

Price (delayed)

$0.04

Market cap

$956,001

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.12

Enterprise value

$111.01M

Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with ...

Highlights
Impel Neuropharma's revenue has surged by 155% YoY and by 10% QoQ
IMPL's net income is up by 31% YoY and by 19% QoQ
The debt has soared by 128% YoY and by 120% from the previous quarter
Impel Neuropharma's quick ratio has shrunk by 98% YoY and by 50% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://impelnp.com
Peers: OMGA

Key stats

What are the main financial stats of IMPL
Market
Shares outstanding
23.9M
Market cap
$956,001
Enterprise value
$111.01M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.29
Earnings
Revenue
$20.99M
EBIT
-$61.9M
EBITDA
-$59.42M
Free cash flow
-$81.98M
Per share
EPS
-$3.12
Free cash flow per share
-$3.45
Book value per share
-$3.87
Revenue per share
$0.88
TBVPS
$1.48
Balance sheet
Total assets
$35.07M
Total liabilities
$126.98M
Debt
$114.8M
Equity
-$91.91M
Working capital
-$101.32M
Liquidity
Debt to equity
-1.25
Current ratio
0.19
Quick ratio
0.09
Net debt/EBITDA
-1.85
Margins
EBITDA margin
-283.1%
Gross margin
52.6%
Net margin
-353.9%
Operating margin
-341.1%
Efficiency
Return on assets
-127.4%
Return on equity
N/A
Return on invested capital
-252.9%
Return on capital employed
N/A
Return on sales
-295%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMPL stock price

How has the Impel Neuropharma stock price performed over time
Intraday
-21.72%
1 week
-89.36%
1 month
-86.76%
1 year
-98.74%
YTD
-98.93%
QTD
-90.7%

Financial performance

How have Impel Neuropharma's revenue and profit performed over time
Revenue
$20.99M
Gross profit
$11.03M
Operating income
-$71.59M
Net income
-$74.28M
Gross margin
52.6%
Net margin
-353.9%
Impel Neuropharma's revenue has surged by 155% YoY and by 10% QoQ
The net margin has soared by 73% YoY and by 26% from the previous quarter
IMPL's operating margin has soared by 69% YoY and by 19% from the previous quarter
IMPL's net income is up by 31% YoY and by 19% QoQ

Growth

What is Impel Neuropharma's growth rate over time

Valuation

What is Impel Neuropharma stock price valuation
P/E
N/A
P/B
N/A
P/S
0.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.29
Impel Neuropharma's EPS has increased by 29% YoY and by 19% from the previous quarter
Impel Neuropharma's equity has decreased by 16% from the previous quarter
Impel Neuropharma's revenue has surged by 155% YoY and by 10% QoQ
The stock's price to sales (P/S) is 98% less than its last 4 quarters average of 2.8

Efficiency

How efficient is Impel Neuropharma business performance
Impel Neuropharma's ROS has soared by 75% YoY and by 29% from the previous quarter
Impel Neuropharma's ROA has decreased by 39% YoY and by 5% from the previous quarter
Impel Neuropharma's ROIC has decreased by 16% YoY and by 6% from the previous quarter

Dividends

What is IMPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMPL.

Financial health

How did Impel Neuropharma financials performed over time
The total assets is 72% smaller than the total liabilities
Impel Neuropharma's quick ratio has shrunk by 98% YoY and by 50% QoQ
IMPL's current ratio has dropped by 96% year-on-year and by 30% since the previous quarter
The debt has soared by 128% YoY and by 120% from the previous quarter
IMPL's debt to equity has dropped by 89% since the previous quarter but it is up by 45% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.